VACCINES AGAINST SARS-COV-2
The present invention relates to a second generation vaccines against COVID-19 to avoid the immunodominant response mediated by the germline region IGHV3-53/IGHV3-66. Such vaccines present several advantages as to avoid propagating the most common escape variants and the generation of potentially harmful autoantibodies. The invention relates also to the use of such vaccines in the prevention or treatment of the SARS-CoV-2 infection or conditions or disorders resulting from such infection..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 27. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
RAPPUOLI RINO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-27, Last update posted on www.tib.eu: 2024-01-03, Last updated: 2024-01-12 |
|---|
| Patentnummer: |
EP4294434 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018907881 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018907881 | ||
| 003 | DE-627 | ||
| 005 | 20240112063220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240105s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018907881 | ||
| 035 | |a (EPA)EP4294434 | ||
| 035 | |a (EPA)75660250 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a RAPPUOLI RINO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a VACCINES AGAINST SARS-COV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-27, Last update posted on www.tib.eu: 2024-01-03, Last updated: 2024-01-12 | ||
| 520 | |a The present invention relates to a second generation vaccines against COVID-19 to avoid the immunodominant response mediated by the germline region IGHV3-53/IGHV3-66. Such vaccines present several advantages as to avoid propagating the most common escape variants and the generation of potentially harmful autoantibodies. The invention relates also to the use of such vaccines in the prevention or treatment of the SARS-CoV-2 infection or conditions or disorders resulting from such infection. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ANDREANO EMANUELE |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 27. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75660250/publication/EP4294434A1?q=EP4294434 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 27 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 12 | ||